4-Antibody, a wholly-owned subsidiary of Agenus Inc., is located in Basel, Switzerland. 4-Antibody has a powerful fully-human antibody drug-discovery technology platform, which is generating an emerging pipeline of antibody therapeutics focused on immuno-oncology.4-Antibody's technology platform, Retrocyte Display®, is designed to generate high quality therapeutic antibody drug candidates quickly using a high-throughput approach incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. We currenly have preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. We are expecting to identify development programs to be in a position to file investigational new drug applications in 2015/2016. Please see our pipeline for more information.